Recent research indicates that selective NMDA receptor GluN2B subunit antagonists, NMDA receptor glycine site partial agonists and mGlu5 negative allosteric modulators may become useful for the treatment of major depressive disorders [31,32,33,34,35]. Here, GRIN2B is linked to major depressive disorder.